About DBV Technologies S.A.
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic Substances
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: DBVT
Companies Related to DBV Technologies S.A.:
- Previous Close: $36.17
- 50 Day Moving Average: $34.66
- 200 Day Moving Average: $35.40
- 52-Week Range: $46,000,000.00 - $24.94
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.95
- P/E Growth: -0.30
- Market Cap: $1.65B
- Outstanding Shares: 46,000,000
- Beta: 1.47
What is DBV Technologies S.A.'s stock symbol?
DBV Technologies S.A. trades on the NASDAQ under the ticker symbol "DBVT."
Where is DBV Technologies S.A.'s stock going? Where will DBV Technologies S.A.'s stock price be in 2017?
6 analysts have issued 12-month target prices for DBV Technologies S.A.'s stock. Their forecasts range from $43.00 to $54.00. On average, they anticipate DBV Technologies S.A.'s share price to reach $47.75 in the next twelve months.
Who owns DBV Technologies S.A. stock?
DBV Technologies S.A.'s stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (8.80%), Janus Capital Management LLC (5.51%), Deerfield Management Co. (3.79%), Arrowpoint Asset Management LLC (1.81%), Perceptive Advisors LLC (1.33%) and Artisan Partners Limited Partnership (1.09%).
Who sold DBV Technologies S.A. stock? Who is selling DBV Technologies S.A. stock?
DBV Technologies S.A.'s stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, FMR LLC and Artisan Partners Limited Partnership.
Who bought DBV Technologies S.A. stock? Who is buying DBV Technologies S.A. stock?
DBV Technologies S.A.'s stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Arrowpoint Asset Management LLC, Acuta Capital Partners LLC and Castleark Management LLC.
How do I buy DBV Technologies S.A. stock?
Shares of DBV Technologies S.A. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of DBV Technologies S.A. stock cost?
One share of DBV Technologies S.A. stock can currently be purchased for approximately $35.78.